MODD

Business Context and Reporting Period

Company: Modular Medical, Inc. (MODD)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended September 30, 2024
Business Overview: A pre-revenue medical device company developing the MODD1, a two-part patch insulin pump. In September 2024, the Company received FDA clearance to market and sell the MODD1 in the United States. The Company operates in a single segment and is classified as a smaller reporting company.

Key Financial Metrics

Cash Flow (Six Months Ended Sept 30, 2024):
- Net cash used in operating activities: $(7,314) thousand
- Net cash used in investing activities: $(1,003) thousand
- Net cash provided by financing activities: $2,978 thousand

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased by $1.27 million (16.0%) for the six months ended September 30, 2024, compared to the prior year period.
  • R&D Expenses: Increased by $0.98 million (16.5%) to $6.907 million, driven by higher stock-based compensation ($0.5M increase), employee-related costs ($0.4M increase), and depreciation ($0.3M increase).
  • G&A Expenses: Increased by $0.295 million (14.6%) to $2.309 million, primarily due to higher legal and professional service fees ($0.3M) and stock-based compensation ($0.1M).
• Liquidity: Cash and cash equivalents decreased from $9.232 million at March 31, 2024, to $3.893 million at September 30, 2024, a reduction of approximately $5.3 million.
• Capital Structure: The Company raised approximately $1.923 million through at-the-market (ATM) stock sales and $1.055 million from warrant exercises during the six-month period.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The Company has incurred operating losses since inception and expects to continue doing so. Management has expressed substantial doubt about the Company's ability to continue as a going concern for at least one year from the filing date. Future operations depend on raising additional capital through equity or debt.
• Commercialization: Following FDA clearance in September 2024, the Company expects R&D and G&A expenses to increase in the second half of fiscal 2025 to support initial commercialization activities.
• Capital Raising: The Company utilized an ATM program to raise funds. Future proceeds are unknown and subject to market conditions. If additional capital is not secured, the Company may need to curtail R&D and commercialization efforts.
• Commitments: As of September 30, 2024, the Company had outstanding purchase orders for machinery and equipment of approximately $0.99 million and a remaining obligation of approximately $0.4 million under a device integration agreement.
• Stock-Based Compensation: Significant expense recognized due to the vesting of options tied to FDA clearance milestones. Approximately $1.588 million in stock-based compensation was recorded for the six months ended September 30, 2024.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $3.9 million cash balance against projected burn rates for commercialization and R&D.
• Capital Needs: Assess the likelihood and terms of future equity or debt financing required to sustain operations beyond the next 12 months.
• Commercialization Timeline: Confirm the specific timeline and costs associated with launching the MODD1 product post-FDA clearance.
• ATM Program Status: Monitor the status of the at-the-market offering and potential dilution from future share sales.
• Going Concern Opinion: Review the auditor's report and management's plan to mitigate the substantial doubt regarding the Company's ability to continue as a going concern.